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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYWerner syndrome (WS) patients exhibit premature aging predominantly in mesenchyme-derived tissues, but not in neural lineages, a
consequence of telomere dysfunction and accelerated senescence. The cause of this lineage-specific aging remains unknown. Here, we
document that reprogramming of WS fibroblasts to pluripotency elongated telomere length and prevented telomere dysfunction. To
obtain mechanistic insight into the origin of tissue-specific aging, we differentiated iPSCs to mesenchymal stem cells (MSCs) and neural
stem/progenitor cells (NPCs). We observed recurrence of premature senescence associated with accelerated telomere attrition and defec-
tive synthesis of the lagging strand telomeres inMSCs, but not inNPCs.We postulate this ‘‘aging’’ discrepancy is regulated by telomerase.
Expressionof hTERTor p53 knockdownameliorated the accelerated aging phenotypeinMSC,whereas inhibitionof telomerase sensitized
NPCs to DNA damage. Our findings unveil a role for telomerase in the protection of accelerated aging in a specific lineage of stem cells.INTRODUCTION
Patients with Werner syndrome (WS) exhibit premature
aging and early onset of a cancer during adulthood (third
to fourth decade) (Chen and Oshima, 2002; Muftuoglu
et al., 2008). Autosomal recessive mutations of the RecQ
helicase WRN are commonly found in the majority of
WS patients, although non-WRN mutations have been
documented (Chen et al., 2003).
WRN is a critical protein for DNA replication, repair,
recombination, and telomere maintenance (Crabbe et al.,
2004; Opresko et al., 2004). An important molecular event
seen inWS pathology is dysfunction of telomeres. It results
in accelerated telomere attrition and failure to fully synthe-
size the lagging strand sister telomeres (Brosh et al., 2001;
Crabbe et al., 2004). Critically short telomeres have been
known to elicit a DNA damage response and trigger cellular
senescence (Abdallah et al., 2009; d’Adda di Fagagna et al.,
2003; Takai et al., 2003). Another observed phenotype in
WS cells is genome instability, perhaps due to deficient
DNA repair and uncapping of chromosome ends. WRN is
known to interact with a number of proteins involved in
DNA repair, recombination, and telomere protection
(Crabbe et al., 2007; Laud et al., 2005; Li and Comai,
2001). These biological functions and molecular mecha-
nisms of WRN serve as the basis for our understanding of
the clinical pathology of accelerated aging (Rossi et al.,
2010). A fascinating clinical feature of WS is the pre-
dominant aging that fibroblasts and mesenchymal tissues
exhibit (Chen and Oshima, 2002; Goto et al., 2013).534 Stem Cell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The AuthorAlthough the spectrum of the aging disorder in many
aspects resembles natural aging (such as graying hair,
cataract, osteoporosis, and atherosclerosis), neurodegenera-
tion, such as that which occurs in Alzheimer and Parkinson
diseases, is seemingly not associated with WS (Goto et al.,
2013; Mori et al., 2003). These observations suggest WS is
not simply an accelerated aging phenomenon, such as
that observed in normally aged people; however, the reason
for this selectively accelerated aging remains unclear.
We reasoned that lineage-specific aging inWS patients is
a consequence of factor(s) that control aging of stem cells.
It gradually develops into diverse clinical presentations,
reflecting the heterogeneity seen in different tissues.
To experimentally query this phenomenon, we generated
patient-specific induced pluripotent stem cells (iPSCs)
and differentiated them to mesenchymal stem cells
(MSCs) and neural progenitor cells (NPCs) to study the
cellular aging phenotype. We identified telomerase as
a critical factor in controlling premature senescence in
specific lineages of stem cells.RESULTS
Reprogramming Prevents Cellular Aging in WS
Fibroblasts
As a consequence of WRN deficiency, WS skin-cultured
fibroblasts divide slowly and rapidly become senescent, a
characteristic of premature aging (Figures S1A and S1B
available online). Senescence and genomic instability ares
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2009). Despite these barriers, we successfully reprog-
rammed WS fibroblasts using efficient polycistronic
lentivirus in combination with inhibitors that target the
TGF-b pathway and the epigenetic modifier HDAC. Four
WS fibroblasts cultures, including a line from a non-classic
WS that expresses wild-type WRN (AG06300), were suc-
cessfully reprogrammed to iPSCs (Table S1). These WS
iPSCsweremaintained in culture formore than 35 passages
without changes in their morphology. WS iPSCs expressed
pluripotencymarkers and showed characteristics of human
embryonic stem cells (hESCs), including the stringent
teratoma formation assay in SCID mice (Figures S1C–
S1E). BrdU incorporation indicated that WS iPSCs syn-
thesized DNA at a slightly slower rate than normal iPSCs;
however, the difference was statistically insignificant
(p = 0.09, t test; Figure S1F). We compared gene expression
profiles before and after reprogramming. More than 800
genes were differentially expressed in the parental
fibroblasts (fold change >2 or <2; p < 0.05; one-way
ANOVA); most were involved in cellular aging (Figures 1A
and 1B). Surprisingly, after reprogramming, nearly all of
the fibroblast differentially expressed genes (99.7%) were
erased in the derived iPSCs. The transcriptome of reprog-
rammed WS iPSCs were highly similar to normal iPSCs
(Figure 1C). Unsupervised whole-genome clustering
demonstrated the WS iPSC transcriptome was indistin-
guishable from normal iPSCs, indicating that reprogram-
ming has reset the aging phenotype.
Restoration of Telomere Function in WS iPSCs
WRN mutant cells display critically short telomeres and
defective synthesis in the lagging strand of sister telomeres,
leading to premature senescence (Crabbe et al., 2004;
Ishikawa et al., 2011; Schulz et al., 1996). Previous studies
demonstrated that telomerase overexpression prevents
the expression of the telomere defect in WS fibroblasts
(Crabbe et al., 2007). As expected, following reprogram-
ming, WS iPSCs showed little deficit of telomere synthesis
as revealed by telomere chromosome-orientation fluores-
cence in situ hybridization (CO-FISH). Most of the cells
could successfully synthesize the lagging strands of their
telomeres despite the lack of WRN protein (Figure 2A).
Normal telomere function in reprogrammed WS cells is
further supported by successful reactivation of telomerase
and expression of telomerase complex genes (TERT,
TERC, and DKC1) (Figures 2B and S2A). The telomere
length of WS iPSCs was elongated to a similar extent as
that observed in normal iPSCs or hESCs (Figure 2C). More-
over, genes thatmaintain telomere stability (shelterin)were
expressed at a level similar to that observed in normal iPSCs
(Figure S2B). These observations indicate at pluripotency
WS cells have corrected their telomere-associated defects.StemRecurrence of Premature Senescence and Telomere
Dysfunction in Differentiated MSCs
Our observations on WS iPSCs telomere function do not
provide a rationale for the premature aging phenotype
observed in affected tissues of patients’ mesenchymal line-
ages, such as bone, vascular cells, dermis, and hair (Chen
and Oshima, 2002; Muftuoglu et al., 2008). We postulated
that in WS, because the premature aging phenotype is
predominantly expressed in mesenchymal lineages as a
consequence of premature senescence, MSC exhaustion
may occur at an early age. To model cellular aging of
MSCs, we differentiated iPSCs to MSCs using a previously
reported protocol (Lian et al., 2010). Both normal and WS
iPSC-derived MSCs expressed positive and negative surface
markers similar to that observed in human bone marrow-
derived MSCs (BM-MSCs) (Figures S3A and S3B). The
iPSC-derived MSCs exhibited multipotency and differenti-
ated to fat, bone, and cartilage-like cells in specific induc-
tion media (Figure S3C). Unlike hESCs/iPSCs, MSCs have
a limited replicative potential due to an end replication
problem (Lu et al., 2013). Comparison of the proliferation
capacity of these cells revealed slower cell proliferation and
early entry to senescence of the WSMSCs (Figures 3A–3C).
Premature senescentWSMSCs expressedmore p53 and the
senescence markers p21 (also known as CDKN1A) and p16
(also known as CDKN2A) (Figure 3D). In late passage, WS
MSCs had shortened telomere length, an evidence of accel-
erated telomere erosion (Figure 3E). BrdU incorporation
experiments indicated a smaller fraction of cells in S phase
for WS MSCs; however, the difference of BrdU incor-
poration in iPSCs was marginal and insignificant (Figures
3F and S1F). CO-FISH telomere analysis revealed a high
incidence of sister telomere loss in the lagging strand
(Figures 3G and 3H). These results are consistent with
the previously reported observation in WS fibroblasts or
WRN-depleted cells (Crabbe et al., 2004). The premature
senescence and defective synthesis of the lagging strand
telomeres in derived MSCs recapitulated that observed in
WS fibroblasts.
Rescue of Premature Senescence by hTERT or p53
Depletion
We speculate the slow cell proliferation and accelerated
senescence found in WS MSCs is due to the downregula-
tion of telomerase activity, which sensitizes cells to DNA/
telomere replication in a WRN-deficient background. To
test this hypothesis we generated hTERT-knockin WS
fibroblasts and subsequently reprogrammed them to
pluripotency. These genetically modified iPSCs showed
similar expression profiles and telomerase reactivation
to that observed in unmodified WS iPSCs (Figure S4A).
Upon differentiation to MSCs (WS-MSCtert), telomerase
activity remained high compared to those derived fromCell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The Authors 535
Figure 1. Reprogramming to Pluripotency Prevents Premature Senescent Phenotype in WS Fibroblasts
(A) Expression microarray analysis comparing the number of differentially expressed genes (fold change > 2; FDR < 0.05) between normal
and WS cells before (fibroblasts) and after reprogramming (iPSCs). Reprogramming reduces the number of differentially expressed
transcripts from 858 to 27.
(B) Gene ontology analysis for the differentially expressed genes in WS fibroblasts based on the cellular process of biological function. The
major categories of the differentially expressed genes are cell aging and cell recognition.
(C) Unsupervised hierarchical clustering for fibroblast and iPSC samples based on the differentially expressed genes identified in WS
fibroblasts. Two hESC lines CT2 and ESI-053 are included.
See also Figure S1.
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Figure 2. Restoration of Telomere Function in Reprogrammed WS iPSCs
(A) Normal synthesis of both the leading and the lagging strand sister telomeres in WS iPSCs by chromosome orientation fluorescence
in situ hybridization (CO-FISH).
(B) Reactivation of telomerase activity in WS iPSCs by telomeric repeat amplification protocol (TRAP). Values represent mean of technical
replicates ± SD (n = 3).
(C) Telomere length in WS iPSCs by Southern blot of terminal restriction fragment (TRF). The differences of telomerase activity and TRF
length between normal and WS iPSCs are not significant (n.s.). Scale bar, 10 mm.
See also Figure S2.
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dence of retroviral gene silencing upon differentiation
because WS-MSCtert expressed similar telomerase activity
to hTERT-knockin WS fibroblasts. These cells remain anti-
biotic resistant, indicative of a lack of silencing of the
retroviral vector. WS-MSCtert showed a higher prolifera-
tion rate and improved replicative potential with reduced
senescence despite the absence of WRN protein (Figures
4A, 4C, and 4D). This hTERT-ameliorated effect was
reversed by prolonged treatment with the telomerase
inhibitor BIBR 1532 (Figures S4C and S4D). To under-
stand how telomerase activity rescues premature aging
in WS MSCs, we examined the expression of the senes-
cence markers p21 and p16, activation of DNA double
strand breaks (p-ATM) and the presence of DNA damage
markers (53BP1 and gH2AX) in normoxia or oxidative
stress induced by hydrogen peroxide. WS-MSCtert
expressed higher p53 and p21 (a target of p53), perhaps
because of the stabilization of p53 by telomeric repeats
(Milyavsky et al., 2001). Nevertheless, activation of p53
was not increased in WS-MSCtert despite the higher basal
level (Figure S4I). Another senescence marker p16, as ex-
pected, was decreased in WS-MSCtert. When WS MSCs
were exposed to H2O2, 53BP1 was activated at low oxida-
tive stress (50 mM), whereas gH2AX was induced at high
oxidative stress (250 mM) accompanied by activation of
ATM (p-ATM) (Figure S4E). The expression of hTERT in
WS MSCs appears to rescue senescence through reduction
of the p16 level (but not of p53/p21) and the DNA dam-
age marker gH2AX. These data support the critical role of
telomerase in cell proliferation and the cell’s replicativeStempotential, as well as in preventing DNA damage and pre-
mature senescence in WRN-deficient cells. We suggest
that, without protection of the telomere by telomerase,
WS cells quickly enter senescence via the p53 pathway.
To verify this postulation, we derived stable p53 knock-
down cells by RNAi (p53i) in WS fibroblasts. When these
p53i WS cells were reprogrammed to iPSCs, they showed
little difference from unmodified iPSCs; however genomic
instability was present (Table S2). Genomic instability due
to p53 depletion in iPSCs has been previously reported
(Kawamura et al., 2009; Mario´n et al., 2009a). Upon dif-
ferentiation to MSCs (WS-MSCp53i), p53 protein remains
low, evidence of persistent expression of p53 shRNA (Fig-
ure S4F). As a consequence in MSCs, p53i enhanced their
proliferative potential and rescued the premature senes-
cence phenotype without the need for high telomerase
activity and long telomere length (Figures 4B–4D). As
expected, WS-MSCp53i expressed less p21 and phosphory-
lated p53 (Figure S4G). Next, we examined the telomere
status in these genetically modified cells. Longer telomere
length was found in WS-MSCtert, but not in WS-MSCp53i,
suggesting a rescue of the accelerated telomere attrition
by telomerase (Figure 4E). CO-FISH analysis revealed a
reduction of defective synthesis for the lagging strand
telomeres in WS-MSCtert, but not in WS-MSCp53i (Figures
4F and 4G). Collectively, these data support the critical
role of telomerase in preventing premature senescence
in MSCs by restoring telomere function. p53 appears to
be a downstream effector because a similar effect was
achieved as a consequence of depleting p53 and bypass-
ing the senescence pathway.Cell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The Authors 537
Figure 3. Recurrence of Premature Senescence and Telomere Dysfunction in WS MSCs
(A) Reduced cell proliferation and replication potential in WS MSCs with continuous culture for 76 days.
(B) Quantitative analysis for percentage of senescent cells in MSCs after 44 days of culture (p11). A significant difference is found between
normal and WS MSCs (p < 0.05).Values represent mean of technical replicates ± SD (n = 3).
(C) Representative images for normal and WS MSCs by SA-b-galactosidase staining.
(legend continued on next page)
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DNA Damage
Because telomerase has a critical function in protection of
telomere erosion in MSCs, we speculate that the neural
lineage telomerase is differentially regulated and protects
neural lineage cells from accelerated senescence. To test
this hypothesis, we differentiated iPSCs to NPCs (Fig-
ure S5A). The derived cells expressed NPC markers NESTIN
and SOX1 and were able to differentiate them to neurons
and astrocytes in neuronal induction media (Figure S5B).
As expected, WRN protein was expressed in both normal
NPCs and MSCs but was undetectable in WRN mutant
WS lines (Figure S5C). We measured telomerase activity
and telomere length in NPCs. A telomeric repeat amplifica-
tion protocol (TRAP) assay showed a higher telomerase
activity in NPCs than in MSCs, although the level was
lower than pluripotent hESCs/iPSCs. To our surprise, the
telomerase activity of normal andWS NPCs was not signif-
icantly different (p = 0.78, t test; Figure 5A). Similarly the
telomere length observed in WS NPCs was comparable to
normal NPCs (Figure 5B). CO-FISH analysis revealed a
low incidence of missing sister telomeres in the lagging
strands indicative of normal telomere synthesis during
replication (Figure 5C). WS NPCs divided actively in cul-
ture and incorporated BrdU at a rate similar to normal
NPCs (Figures 5D and S5D). No apparent premature senes-
cence was observed in NPC cultures. Our observations sug-
gest relatively normal cellular proliferation and telomere
function in NPCs, consistent with the clinical phenotype
of WS (Goto et al., 2013). Because telomerase is expressed
in NPCs, and ectopic expression of hTERT in MSCs is able
to rescue premature senescence in the absence ofWRN (Fig-
ure 4), we tested whether telomerase inhibition in WS
NPCs sensitizes cells to accelerated aging. Senescence-asso-
ciated (SA)-b-galactosidase activity was not detected upon
3 days of treatment with the telomerase inhibitor BIBR
1532. We speculate that the long telomere reserves in
NPCs may prevent these cells from senescence (Taboski
et al., 2012). However, analysis of the DNA damage marker
gH2AX indicated a telomerase-sensitive response. BIBR
1532 sensitized WS NPCs to gH2AX, a chromatin marker
induced by replicative stress or DNA damage. All WS lines
showed a remarkable increase of gH2AX; however, the
change in BrdU incorporation (an indication of mitotic(D) Expression of p53 and senescence markers p21 and p16 proteins b
and p16.
(E) Accelerated telomere attrition at late passage (p17) of WS MSCs a
(F) BrdU incorporation between normal and WS MSCs. The difference
(G) Increased incidence of defective synthesis for the lagging stran
metaphase.
(H) Quantification of (F). Values represent mean ± SEM (at least 15 m
Scale bar, 100 mm (C) or 10 mm (G). See also Figure S3.
Stemarrest) and NESTIN expression (an indication of undiffer-
entiated state for NPCs) did not differ between normal
and WS cells (Figure 5E). A longer inhibition of telomerase
for 6–8 days slowed their proliferative capacity; this phe-
nomenon was more prominent in WS NPCs (Figure S5E).
However, inhibition of telomerase in WS NPCs decreased
the p53 level and its target p21, whereas p16 was not
detectable (Figure S5F).The consequent change in the p53
level in WS NPC survival remains to be addressed in future
studies. In summary, our data suggest that telomerase
benefits cell growth and prevents premature aging or
DNA damage by correcting telomere function in a specific
lineage of WS stem/progenitor cells; it is more severely
compromised in MSCs and to a lesser extent in NPCs
and iPSCs.DISCUSSION
Our data demonstrate premature senescence caused by
WRN loss can be reversed by nuclear reprogramming,
possibly as a consequence of reactivation of telomerase
machinery that corrects the telomere defect. Reprogram-
ming of normally aged fibroblasts or diseases of laminopa-
thies and Hutchinson-Gilford Progeria syndrome have
been reported (Lapasset et al., 2011; Liu et al., 2011; Zhang
et al., 2011). Our observations highlight telomere function
in WS cells, because abnormal telomere homeostasis is a
critical molecular event in WS pathology (Chang et al.,
2004; Crabbe et al., 2004; Ishikawa et al., 2011; Laud
et al., 2005; Multani and Chang, 2007). Telomere length
in pluripotent WS cells appears to be normal. With differ-
entiation premature senescence recurs, and aberrant telo-
mere synthesis is found in derived MSCs, but not in
NPCs, indicative of a lineage-specific aging phenomenon.
This observation is consistent with the clinical phenotype
ofWS, wheremesenchymal tissues are severely affected but
mild or no symptoms are associated with neural lineages
(Goto et al., 2013). The inability to perform systematic
studies of different cell types or tissues during embryonic
development and in adulthood validates iPSC technology
as a valuable tool to study its pathogenesis. By comparing
the different stem/progenitor cells, we identified a dramatic
difference in telomerase activity. In line with other studies,y Western blot analysis. WS MSCs express more proteins of p53, p21,
s revealed by TRF Southern blot.
is significantly different (p < 0.05).
d telomeres by CO-FISH. Arrows indicate the missing telomeres at
etaphase cells were analyzed).
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Figure 4. Rescue of Premature Senes-
cence in WS MSCs by Overexpression of
hTERT or Knockdown of p53
(A and B) Increased cell proliferation and
replicative potential in WS MSCs by over-
expression of hTERT (A) or by p53 knock-
down (p53i) (B).
(C) The percentage of SA-b-galactosidase-
positive cells is reduced by hTERT over-
expression or by p53i. Values represent
mean of technical replicates ± SD (n = 3).
(D) Representative images of SA-b-galac-
tosidase staining.
(E) WS MSCs expressing hTERT show
elongated telomere length compared to
unmodified MSC. Telomere length is slightly
shortened or unchanged in p53i MSCs.
(F) CO-FISH analysis for the lagging
strand telomeres in hTERT-expressing and
p53i WS MSCs. Arrows indicate the missing
telomeres from the lagging strand.
(G) Quantification of (F). Values represent
mean ± SEM (at least 15 metaphase cells
were analyzed).
Scale bar, 100 mm (D) or 10 mm (F). See also
Figure S4.
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ity declines with differentiation (Armstrong et al., 2000;
Yang et al., 2008).MSCs and fibroblasts express low telome-
rase activity, which explains the vulnerability of these
cells to replication-induced senescence and telomere
dysfunction.
The present study supports the critical role for telome-
rase in preventing specific lineages of cells from acceler-
ated aging, and it may affect stem cell renewal and their
capacity for regeneration (Blasco, 2007). Our observation
is consistent with the Wrn knockout mouse model,
which does not recapitulate the pathogenesis of the dis-
ease unless it is expressed on a background of Terc/
(Chang et al., 2004; Lombard et al., 2000). How telome-540 Stem Cell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The Authorrase rescues telomere dysfunction is not clear; however,
telomerase was reported to extend telomeres and rescue
premature aging and reverse tissue degeneration in aged
Terc/ mice with shortened telomeres (Jaskelioff et al.,
2011; Samper et al., 2001). An unexpected result from
our study is the moderate upregulation of p53 and hence
p21 in hTERT-expressing WS cells (Figure S4E). Similar
moderate increase of p53 upon hTERT overexpression
was also observed in wild-type MSCs (Figure S4H). Short-
ened telomeres are postulated to activate p53, leading
primary cells to senesce (d’Adda di Fagagna et al.,
2003). Intriguingly, our data show that hTERT expression
in WS MSCs, albeit enhancing their proliferation poten-
tial and slowing telomere erosion, increased p53 ands
Figure 5. Telomerase Protects and
Prevents NPCs from DNA Damage
(A) Comparison of telomerase activity
between normal and WS NPCs and MSCs,
respectively. The difference between
normal and WS NPCs is not significant.
Values represent mean of technical repli-
cates ± SD (n = 3).
(B) Telomere length in normal and WS NPCs
by TRF Southern blot.
(C) CO-FISH analysis for the lagging strand
telomeres in WS NPCs. Few chromosomes
show missing telomeres at the lagging
strand.
(D) Growth dynamics of NPCs in monolayer
culture.
(E) Treatment of telomerase inhibitor BIBR
1532 sensitizes WS NPCs to DNA damage by
increasing gH2AX. Active dividing cells and
NPC markers were shown by BrdU incorpo-
ration (22 hr incubation) and NESTIN
expression, respectively. Values represent
mean of technical replicates ± SD (n = 3).
Scale bar, 10 mm. See also Figure S5.
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NPCs decreased p53/p21 (Figure S5F). One possible
explanation for this phenomenon is that longer telomere
repeats stabilize p53 and thus slow their turnover (Mi-
lyavsky et al., 2001). However, the detailed mechanism
remains to be elucidated.
Telomerase reactivation is a characteristic of successful
reprogramming to pluripotency and important for self-
renewal in ESCs (Batista et al., 2011; Marion et al.,
2009b). We attempted to suppress telomerase activity in
WS iPSCs using the same BIBR 1532 concentration inStemWS-MSCtert. However, telomerase is expressed so abun-
dantly in iPSCs that less than 20% of inhibition was
achieved. At this level no change in morphology, decrease
of SSEA4 (a surface marker for iPSCs), or BrdU incorpora-
tion was observed (Figure S1G). Upon differentiation and
lineage specification, telomerase is ‘‘programmed’’ to
different activity levels, and thus different cells show vari-
able vulnerability to aging. Differential telomerase activity
in various stem cells has been documented (Dolci et al.,
2002; Morrison et al., 1996; Zimmermann et al., 2003).
We compared three different stem cell types: the hESCsCell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The Authors 541
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adult bonemarrow, and the NPCs derived from the cortical
region of human fetal brain for their telomerase activity.
The result confirmed a notable difference in telomerase ac-
tivity among these stem cell types (Figure S2C). In addition
to telomerase, the shelterin complex caps and stabilizes the
telomeres (Palm and de Lange, 2008). Interestingly, a com-
parison of shelterin gene expression in the derived normal/
WS stem cells indicated a significant difference for some of
the capping genes, such as TRF1, TRF2, and POT1 (Fig-
ure S2B). Coincidently, WRN cooperates with POT1,
TRF1, and TRF2 for proper telomere maintenance (Opresko
et al., 2002, 2004, 2005). Among them, TRF2 and POT1 are
known to repress ATM/ATR cascades in response to uncap-
ping of chromosomal ends (Denchi and de Lange, 2007).
TRF1 is abundantly expressed in pluripotent stem cells
and restricted to some other adult stem cells, as TRF1 is a
direct transcriptional target of Oct3/4 (Schneider et al.,
2013). These observations suggest that by modulating the
telomere-regulating machinery, it is possible to rescue or
slow the accelerated aging. Next, targeting the tumor sup-
pressor p53 can mechanically rescue senescence; however,
it increases the incidence of tumorigenesis and genomic
instability. A major cause in patients with WS is the devel-
opment of mesenchymal cancers, such as soft tissue sar-
coma and osteosarcoma (Chen and Oshima, 2002). It is
proposed that immortalization of mesenchymal cancers
in WS is acquired by alternative lengthening of the telo-
mere (ALT) instead of telomerase activation (Laud et al.,
2005; Multani and Chang, 2007). Although we did not
observe immortalization of MSC cultures, our cell model
may provide an opportunity to study the unique feature
of tumorigenesis in WS. In the present study we focused
on stem or progenitors cells; the exhaustion of these pro-
genitors is believed to arise with organismal aging. Termi-
nally differentiated cells, such as fibroblasts, bone cells,
and endothelial and smooth muscle cells, as contrasted to
neurons, may provide more insight into the underlying
mechanism of accelerated aging.EXPERIMENTAL PROCEDURES
Cell Lines and Cultures
We obtained WS and normal control fibroblasts from Coriell Cell
Repositories. Additional normal control fibroblasts (BC, AN1,
AN2, and AN3) were obtained from healthy donors at the
Clinical Center of National Institutes Health with written con-
sent. hESC lines CT2 and ESI-053 were obtained from University
of Connecticut Stem Cell Core and BioTime, respectively. Bone
marrow MSCs (BM-MSCs) and ReNcell CX human NPCs
(CX-NPCs) were purchased from StemCell Technologies and
Millipore, respectively. All cell cultures were maintained as sug-
gested by the suppliers.542 Stem Cell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The AuthorGeneration and Characterization of iPSCs
We reprogrammed WS fibroblasts with high-titer polycistronic
lentivirus-expressing human OCT4, SOX2, KLF4, and c-MYC
(hSTEMCCA) (Somers et al., 2010). Four days after transduction,
cells were transferred to MEF feeders in iPSC culture medium sup-
plemented with HDAC and TGF-b RI kinase inhibitors (Millipore,
cat. no.CS204423,CS204420) for 12 days.WS iPSC colonies started
to appear 2weeks after transduction.Colonieswerepicked fromday
30 to 40 and expandedonMEF feeders inhESCmediumcontaining
80% KO Dulbecco’s modified Eagle’s medium (DMEM), 20% KSR,
1%nonessential amino acids, 1%GlutaMAX, 0.1mM b-mercaptoe-
thanol, and 10 ng/ml bFGF. iPSCs were characterized by expression
of pluripotency markers NANOG, SOX2, OCT4, SSEA3, SSEA4,
TRA1-60, and TRA1-81 using immunofluorescence staining. iPSC
pluripotency was tested by injecting cells into SCID mice at the
kidney and testis capsules and harvested for histologic analysis
(Applied Stem Cells). Karyotyping was performed by the WiCell
Cytogenetics Lab. To generate telomerized and p53 knockdown
cells, we transduced WS fibroblasts with retrovirus-expressing
hTERT (Addgene plasmid 1773) or p53 shRNA (Santa Cruz)
and selected by 100 mg/ml hygromycin B or 1 mg/ml
puromycin. Stable cultures were reprogrammed by hSTEMCCA as
described above.
Differentiation and Characterization of MSCs Derived
from iPSCs
To derive MSCs, we trypsinized iPSCs to single cells and plated
themon a gelatin-coated dish inMSCdifferentiationmedium con-
taining 20% of MSC-qualified FBS (Life Technologies), 10 ng/ml of
bFGF, PDGFAB, and EGF (all Peprotech) in alphaMEM (Lian et al.,
2010). Differentiating cells were split by trypsin for 3–4 timeswhen
becoming confluent. After 2 weeks, cells were sorted for CD105+/
CD90+/CD24 using fluorescence-activated cell sorting (FACS)
Aria (BD Biosciences). Sorted cells were allowed to grow for 3–
4 days and subsequently plated on a plastic dish at 1 3 104 cells/
cm2 in MSC medium containing 10% MSC-qualified FBS, 5 ng/
ml bFGF in low-glucose DMEM. MSCs were split every 4 days,
and a growth curve was constructed by direct cell counting at
each passage. For characterization of MSCs, we analyzed expres-
sion of MSC phenotype (CD73+, CD90+, CD105+, CD44+,
CD166+, CD29+, CD34, CD45, CD14, CD19, and HLA-DR)
by flow cytometry. All antibodies and control immunoglobulin
G isotypes were purchased from BD Biosciences. BM-MSCs
were included as a positive control. To test multipotency, we
differentiated MSCs to adipocytes, osteocytes, and chondrocytes
by STEMPRO Adipogenesis, Osteogenesis, and Chondrogenesis
Differentiation Media (Life Technologies). Adipocytes and osteo-
cytes were stained with Nile Red and Alizarin Red S after 4 and
2weeks of differentiation, respectively. Cell aggregates of chondro-
cytes were fixed and sectioned for SafraninO staining after 2 weeks
of differentiation.
Differentiation and Characterization of NPCs Derived
from iPSCs
To derived NPCs, we formed embryoid bodies (EBs) from iPSCs
cultured on Matrigel with mTeSR1 medium (StemCell Technolo-
gies) on AggreWell (Marchetto et al., 2010). EBs were induced fors
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(StemCell Technologies) for 5 days on AggreWell and then trans-
ferred to poly-L-ornithine (PLO)/laminin-coated plates for another
7 days. Neural rosettes were collected by treating cell aggregates
with Neural Rosette Selection Reagent and then were replated on
PLO/laminin-coated plate. NPCs were allowed to grow to conflu-
ence from neural rosettes and thereafter passed every 4 days.
NPCs were cultured as monolayer on PLO/laminin-coated plates
in N2B27 medium containing 0.5% N2, 1% B27, EGF, and bFGF
(20 ng/ml of each) in DMEM/F12 with GlutaMAX (Life Technolo-
gies). For characterization of NPCs, we analyzed expression of
neural stem markers NESTIN (Millipore) and SOX1 (BD Biosci-
ences) by immunofluorescence staining. To test multipotency,
we plated NPCs on Matrigel-coated plates and cultured them in
N2B27 medium with the withdrawal of EGF and bFGF and
inclusion of neurotrophic factors BDNF, CNTF, GDNF, and IGF1
(10 ng/ml of each) (Peprotech) and 1 mM of cAMP (Wang et al.,
2013). After 2 weeks of differentiation, cells were examined for
the expression of neuronal markers TUJ1, MAP2, and DCX and
the astrocyte marker GFAP by immunofluorescence staining.
Telomerase Activity Assay by TRAP
Wemeasure telomerase activity by TRAP assay (Wright et al., 1995)
using the TRAPeze RT Telomerase Detection Kit (Millipore). Crude
protein lysate was extracted and adjusted to 0.5 mg/ml. Lysate (1 mg)
was incubated with the TRAPeze RT reaction mix at 30C for
30 min. The telomerase product was amplified by real-time PCR
using hot-start Taq polymerase with the inclusion of a TSR8
standard curve. Telomerase activity was normalized by the TSK
and expressed as the relative level to hESCs. All TRAP assays were
performed as three independent technical replicates.
Southern Blot Analysis of Terminal Restriction
Fragment Lengths
Telomere length was determined as previously described (Kimura
et al., 2010). Genomic DNA was digested with RsaI and HinfI
overnight and resolved in 0.6% agarose gel. DNA was transferred
to nylon membrane (Ambion) by capillary method overnight.
Membrane was hybridized to DIG-labeled telomere probe
(CCCTAA)3 at 42
C overnight. After stringent wash (0.1% SDS in
2X SSC), membrane was blocked and incubated with anti-DIG-
AP antibodies for half an hour at room temperature. Terminal
restriction fragment (TRF) was measured by the intensity of the
AP substrates using chemiluminescence detection. All reagents
were from the Telo TAGGG Telomere Length Assay Kit (Roche).
Average TRF length was calculated by mean TRF length =
S (ODi) / S (ODi/MWi), where OD is the optical density at position
i and MWi is the TRF length at that position.
Telomere CO-FISH
Telomere CO-FISH was performed as previously described, with
minor modifications (Crabbe et al., 2004). Briefly, dividing cells
were incorporated with 7.5 mM BrdU and 2.5 mM BrdC for
approximately 1 doubling time (21 hr for iPSCs, 26–35 hr for
MSCs, and 30 hr for NPCs). Metaphases cells were enriched by
treatment of Colcemid for 4–8 hr and fixed with fresh methanol
and glacial acetic acid (3:1) at 4C overnight. Cells were washedStemand dropped on HCl-treated glass slides. To remove newly
synthesized BrdU/BrdC-incorporated DNA strands, cells were
stained with 0.5 mg/ml Hoechst 33258, exposed to UV light for
half an hour, and then digested by Exonuclease III (10 U/ml)
for 10 min at room temperature. Hybridization was performed
using fluorescence-labeled PNA telomere probes (PNA Bio) for
the leading stand (TTAGGG)3 and lagging strand (CCCTAA)3,
sequentially hybridized at room temperature for 2 hr. Slides
were washed twice in 70% formamide at room temperature
followed by three washes in 0.23 SSC at 57C. Slides were
stained with DAPI and visualized in Aviovert 200 Inverted
Fluorescent Microscope (Zeiss) using the 1003 oil lens. A total
number of 15–20 metaphases per sample were analyzed and
represented as mean ± SEM.
SA-b-Galactosidase Assay
We detected cell senescence by SA-b-gal cytochemical staining
(Sigma-Aldrich). Adherent cells on the culture dish were fixed
with 2% formaldehyde and 0.2% glutaraldehyde for 6 min and
stained with staining solution containing 5mMpotassium ferricy-
anide, 5 mM potassium ferrocyanide, and 1 mg/ml X-gal at pH 6
overnight. Alternatively, SA-b-gal activity wasmeasured by fluores-
cence substrates (Debacq-Chainiaux et al., 2009). We treated cells
with 100 nM of lysosomal inhibitory drug Bafilomycin A1
(Sigma-Aldrich) for 1 hr. Then a b-gal substrate C12FDG (Life
Technologies) that becomes fluorescent after enzymatic cleavage
was incubated at a final concentration of 33 mM for 2 hr. Cells
were washed and trypsinized for FACS analysis. Fibroblast culture
of low passage number was included as negative control for
senescence. All experiments were performed in triplicate wells
and represented as mean ± SD.
BrdU Incorporation and Flow Cytometry
Tomeasure DNA synthesis at S phase, we incubated actively diving
cells with 10 mM BrdU for 45 min (iPSCs) or 2 hr (MSCs/NPCs).
Cells were fixed, permeabilized, and treated with DNase I
and then incubated with fluorescein-isothiocyanate-labeled anti-
BrdU antibodies (BD Biosciences). iPSCs were costained with
SSEA4, and NPCs were costained with NESTIN for gating of undif-
ferentiated cells. DNA content was stained by 7-AAD. Cells were
washed and analyzed by FACSAria (BD Biosciences). To measure
cell proliferation and DNA damage in NPCs with BIBR 1532 treat-
ment, we labeled cells with BrdU for 22 hr and incubated cells with
Alexa Fluor 647-labeled anti-gH2AX (pS139) (BD Biosciences). All
experiments were performed in triplicate wells and represented
as mean ± SD.
Microarray Analysis and Bioinformatics
We profiled gene expression by GeneChip Human Gene 1.0 ST
Array (Affymetrix). Total RNA (100 ng) was converted to cRNA
by in vitro transcription of the T7-tagged cDNA using the Ambion
WT Expression Kit (Ambion). cRNA (10 mg) was converted to frag-
mented and labeled cDNA probes using theWT Terminal Labeling
and Control Kit (Affymetrix). cDNA probes were hybridized to the
chips overnight at 45C and stained at the GeneChip Fluidics
Station 450. Signals were scanned by GeneChip Scanner 3000
7G. Microarray data were analyzed by Partek Genomics Suite 6.6Cell Reports j Vol. 2 j 534–546 j April 8, 2014 j ª2014 The Authors 543
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Transcriptome profiles were compared using principal component
analysis (PCA) and unsupervised hierarchical clustering of all
genes by comparing the sample dissimilarity using Pearson
correlation. To analyze differentially expressed genes in WS fibro-
blasts, we removed a batch effect due to scan date and compared
the difference of the genes by one-way ANOVA. We clustered the
iPSC/hESC and fibroblast samples based on the differentially
expressed gene sets. Genes with a fold change >2 or <2 and
p value <0.05 with a false discovery rate (FDR) <0.05 were sub-
mitted for gene ontology analysis based on the category of biolog-
ical function. All microarray array experiments were repeated as
duplicate experiments for each sample.
Western Blot Analysis
Western blot analysis was performed as previously described
(Cheung et al., 2011). Primary antibodies used include anti-
WRN (Sigma-Aldrich, clone 195C), anti-gH2AX (Ser139)
(Millipore, clone JBW301), anti-p53 (Santa Cruz Biotech, sc-
126), anti-a-actinin (Santa Cruz Biotech, sc-17829), anti-p16
(Santa Cruz Biotech, sc-468), anti-p21 (Cell Signaling, #2946),
anti-phospho-ATM (S1981) (Abcam, clone EP1890Y), anti-53BP1
(Santa Cruz Biotech, sc-22760), and anti-phospho-p53 (Ser15)
(Cell Signaling, #9284).
Statistical Analysis
All comparisons between normal and WS samples were tested by
unpaired, two-tailed Student’s t test. A p value <0.05 was consid-
ered statistically significant.
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